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Abstract: The biomimetic synthesis of aromatic polyketides from 
macrocyclic substrates by means of catalyst-controlled transannular 
cyclization cascades is described. The macrocyclic substrates which 
feature increased stability and fewer conformational states were 
thereby transformed into several distinct polyketide scaffolds. The 
catalyst-controlled transannular cyclizations selectively led to 
aromatic polyketides with a defined folding and oxygenation pattern, 
thus emulating b-keto-processing steps of polyketide biosynthesis. 
Aromatic polyketides are among the most important natural 
product scaffolds in medicinal chemistry and essential for 
antibiotic and cancer research.[1] Their fascinating biosynthesis 
involves the formation of linear poly-b-carbonyls which are 
transformed in divergent, enzyme-controlled reaction cascades 
(Scheme 1a).[2–6] The selective cyclization of linear polyketide 
chains to access novel structural versatility has hence attracted 
enormous interest.[7] However, the extraordinary reactivity and 
the high number of reactive conformations of native polyketide 
substrates have hampered the selective catalyst-controlled 
folding and cyclization.  
Our previous efforts were engaged in polyketide cyclizations of 
artificial aldehyde substrates with pre-organizing aromatic 
moieties.[8a–g] The mild substrate preparation and the observed 
control over increasingly complex substrates[8g] thereby indicated 
the feasibility of small-molecule catalyzed, divergent cyclizations 
of native polyketides, if the reactivity and selectivity requirements 
are met. Seminal work by Collie[9], Birch,[10] Harris,[11] Money,[12] 
Bringmann[13] and others[14–16] elegantly demonstrated the 
prospects of using linear polyketide chains as competent 
substrates in stoichiometric cyclizations, but also that complex 
product mixtures are obtained with larger systems. Analogous to 
the early methods for stereoselective synthesis,[17–19] we thus 
envisaged that macrocyclic polyketide substrates would impart a 
reduced number of reactive conformations amenable to selective 
transannular cyclization cascades to various polyketide scaffolds 
(Scheme 1b). Notably, the macrocyclic substrates correspond to 
products of a hypothetical Claisen condensation at the termini of 
native, linear polyketide chains. Compared to their acyclic 
congeners, the ring-strain of the macrocycles increases stability 
preventing uncatalyzed background reactions,[8h] thus allowing to 
study divergent, catalyst-controlled cyclizations. The biosynthetic 
pathways would be reentered after a transannular cyclization in 
subsequent retro-Claisen or retro-aldol reactions, rendering 
macrocyclic polyketide substrates suitable precursors for 
aromatic polyketide natural products. Partial reduction of the 
substrates furthermore emulates b-keto-processing,[2] whereas 
small-molecule catalyst-controlled cyclizations would provide a 
means for controlling the oxygenation and folding pattern of plant, 
fungal or bacterial polyketide natural products.[20]  
Scheme 1. a) The divergent biosynthetic pathways lead to remarkable 
polyketide diversity. b) Macrocyclic polyketide substrates (formal products of 
Claisen condensations at the termini of native, linear polyketide chains) are 
prepared from a synthetic precursor by ozonolysis. Divergent, catalyst-
controlled transannular polyketide cyclization cascades govern the 
oxygenation and folding pattern of polyketide natural products, such as the 
shown examples. F = fungal. S = bacterial (streptomyces). CoA = coenzyme A. 
To validate this hypothesis, we selected cyclohexaketides as 
suitable substrates and prepared the corresponding precursors 
by a Birch reduction from the aromatic diol 1[21] followed by a 
double oxidation to diene 3, or a monosilylation and oxidation to 
















b) Transannular polyketide cyclization cascades (this work)
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Scheme 2. Synthesis of precursors 3 and 4 by a Birch reduction:[22] a) Li, 
MeOH, THF, NH3, 99%; b) IBX, DMF, 80%; c) i. TESCl, imidazole, DMF, 55% 
ii. DMP, KHCO3, CH2Cl2, 61%. IBX: 2-Iodoxybenzoic acid. DMP: Dess-Martin
periodinane. 
A mild two-fold ozonolysis of 3 subsequently allowed the in situ 
preparation of the desired cyclododecanehexaone 5 as a 1:1.6 
mixture of two tautomers (Scheme 3a). Remarkably, the 
substrate solution was stable for several days at room 
temperature if kept in the dark, whereas the native, linear 
polyketide chains spontaneously cyclize even under mild 
conditions.[23] Having sufficiently diminished the reactivity to 
circumvent spontaneous transformations, we began the 
investigation of the selective cyclizations (see page S15 for an 
overview). Interestingly, the transannular aldol addition was 
efficiently induced by the addition of K3PO4, giving the hemiketal 
(±)-6 (99% by NMR) (Scheme 3b).  We next explored conditions 
for cyclization cascades comprising retro-Claisen and retro-aldol 
transformations to provide the anticipated aromatic polyketide 
natural products. Notably, the addition of stoichiometric triflic acid 
(TfOH) led to a selective aldol addition / retro-aldol / aromatization 
/ chromone formation cascade[24] to product 8 in an excellent 
yield of 94%, while shorter reaction times revealed hemiketal 7 
as intermediate (Scheme 3c). With aqueous NaOH/NaH2PO4, we 
observed a divergent and smooth reaction to regioisomeric 
fungal or bacterial polyketide products 9–12, as determined by 
the directionality of bond cleavage in the retro-Claisen step (F vs. 
S, Scheme 3d).[20,24] Interestingly, the fungal and bacterial 
pathways could converge to identical polyketide product such as 
10.[25] However, the sensitive naphthoic acid 9F intermediate with 
a fungal polyketide pattern was observed in solution, which 
rapidly decarboxylated to naphthalene-triol 10F upon isolation. 
Without catalysts, the bacterial naphthoic polyketides 11S (62%) 
and 12S (16%) are obtained as the major products and were 
found to be stable.[24] The interconversion of 11S to 12S and the 
decarboxylation of 12S to 10F was not observed, further 
supporting the notion of regiodivergent retro-Claisen reactions. 
To our delight, the addition of the Takemoto catalyst[26] led to an 
inversion of regioselectivity (83% and 14% isolated yield for 10F 
and 11S, respectively), indicating the viability of small-molecule 
catalysis to govern polyketide cyclization cascades. Intriguingly, 
the extent of divergent cyclizations was further noticeable when 
employing the organic base diazabicycloundecen (DBU), leading 
to the differently folded product 13S (36%), together with 10F 
(37%) and intermediate 14F (26%, Scheme 3e).[24] Subsequent 
aerobic oxidation[27] of 13S led to naphthoquinone 15S (76%) with 
reported activity against mycobacterium tuberculosis.[28,29] 
Moreover, in DBU in acetonitrile exclusively yielded the fungal 
intermediate 14F (63%), which was eliminated to 10F and 
oxidized to the biologically active naphthoquinone 16F (96%).[29] 
Scheme 3. Substrate synthesis and transannular polyketide cyclizations. 
[a] Yield determined by NMR using internal standards. [b] Isolated yield.
[c] Polyketide patterns are indicated in bold and the folding modes denoted in
superscript and by color code: F (blue, fungal) C(4)-C(9) and C(2)-C(11); S (red,
bacterial) C(10)-C(5) and C(12)-C(3);[20,24] undifferentiated (green); chromone
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b) Aldol addition and formation of the hemiketal intermediate (±)-6
a) Macrocyclic polyketide substrate synthesis
c) Aldol → retro-aldol → aromatization → hemiketal/chromone formation cascade
d) Catalytic aldol → retro-Claisen → aldol (→ decarboxylation) cascade[c]
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Scheme 4. Transannular cyclization of a partially reduced macrocyclic polyketide substrate with catalyst control over the oxygenation pattern. [a] Yield determined 
by NMR using an internal standard. [b] Reactions performed with 10.0 µmol of substrate 17 in CDCl3 (7.00 mmolL-1). 
We next set out to investigate whether the oxygenation pattern 
of partially reduced aromatic polyketide products may be 
governed by small-molecule catalysis (see page S35 for an 
overview). To emulate enzymatic keto-processing (Scheme 
4a),[2] the partially reduced precursor 4 was ozonolyzed and 
treated with catalytic amounts of HCl to induce a mild 
deprotection, affording substrate 17 as a mixture of several 
tautomers (Scheme 4b). Since five different aldol addition 
products are feasible from the transannular aldol cyclization of 
substrate 17,[24] a precise differentiation is required to control the 
oxygenation pattern by small-molecule catalysts. Gratifyingly, 
thiourea catalysts initiated the divergent aldol additions, forming 
differently oxygenated intermediates (±)-18 and (±)-19 
(Scheme 4c). The Takemoto catalysts were found to be 
particularly active and the catalytic performance and selectivity 
with modifications of the basic functional group and the backbone 
were thus tested. Experiments with imidazole-based catalyst (cat. 
1) showed good yields but moderate selectivity (22% (±)-18, 40%
(±)-19), whereas a catalyst bearing a pyridine moiety (cat. 2) 
increased the overall yield (21% (±)-18, 53% (±)-19). Catalysts 
with secondary amine moieties (cat. 3 or cat. 4) led to little or no 
activity and a propyl-linked tertiary amine (cat. 5) also provided 
low conversions (3% (±)-18, 6% (±)-19). However, the ethylene 
bridged tertiary amine congener (cat. 6) revealed a high 
selectivity and excellent yields (15% (±)-18, 85% (±)-19).[24] 
Isolation of the sensitive product (±)-19 (72%) allowed to 
determine the relative diastereomeric configuration (NOE 
measurements) and also the aldol addition product (±)-18 with a 
different oxygenation pattern was isolated in low amounts (10%). 
The catalyst-controlled aldol addition was next combined with the 
developed protocols to complete the cyclization cascades to 
aromatic polyketide natural products as compared to reactions 
without thiourea catalysts. Treatment of the partially reduced 
macrocycle 17 with DBU in acetonitrile without cat. 6 yielded the 
unknown naphthalene diol 20S, which decomposed over the 
course of a few hours even under inert conditions (Scheme 5a, 
34%).[24] Strikingly, the transformation of 17 using cat. 6 affected 
a catalyst-controlled aldol / retro-Claisen / aldol condensation / 
decarboxylation cascade to fungal polyketide 21F with excellent 
selectivity (63% isolated yield). Moreover, while treatment of the 
macrocycle 17 with excess TfOH only led to decomposition, 
addition of cat. 6 (15 mol%) gave (±)-19 in 71% isolated yield, 
which could be converted to chromone 22 using equimolar 
amounts of TfOH (Scheme 5b, 49%).[24] To further demonstrate 
the utility of the catalyst-controlled polyketide cyclization 
cascades for natural product synthesis, we examined the aerobic 
oxidation of naphthalene diol 21F, which efficiently provided 
plumbagin (23F) and 7-methyl-juglone (24F) (Scheme 5c).[24,29]  
Scheme 5. Catalyst-controlled transannular polyketide cyclization cascades of 
partially reduced macrocyclic polyketides. [a] Reactions performed with 
10.0 µmol of substrate 17 in CDCl3 (7.00 mmolL-1). [b] Yield determined by 
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a) Catalyst-controlled oxygenation by an aldol → retro-Claisen → aldol/decarb. cascade[a]
b) Catalyst-controlled oxygenation by an aldol → retro-aldol → hemiketalization cascade
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In conclusion, a regioselective methodology for biomimetic 
polyketide cyclization cascades of macrocyclic polyketide 
substrates was developed. The substrates showed significantly 
improved stability, allowing selective cyclizations controlled by 
small-molecule catalysts that govern the folding and oxygenation 
pattern of nonreduced and partially reduced aromatic polyketide 
products. Chromones were obtained by an aldol addition / retro-
aldol / aromatization / hemiketalization / dehydration mechanism 
while aromatic polyketides with a fungal or bacterial folding 
pattern resulted from an aldol addition / divergent retro-Claisen / 
aldol condensation / decarboxylation sequence. The addition of 
thiourea catalysts to a partially reduced substrate selectively led 
to a fungal naphthalene diol, which was aerobically oxidized to 
naphthoquinone natural products. The synthesis of the 18 
isolated cyclization products from the macrocyclic substrates 
underscore the versatility of divergent synthesis and an exciting 
avenue for regioselective catalysis. It is thus anticipated, that this 
divergent biomimetic late-stage catalysis strategy will provide an 
alternative to combinatorial polyketide biochemistry.  Our current 
studies focus on the control over linear and angular aromatic 
structure from larger macrocyclic polyketide substrates, 
transannular cascades to nitrogen heterocycles and the 
application of novel catalysis concepts.  
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